-
A new drug of Zizhu pharmaceutical, mifepristone tablet (10mg), completed a multicenter clinical study
Time of Update: 2014-08-13
It is understood that hysteromyoma is the most common benign tumor of female genitalia, which is common in women between 30 and 50 years old According to the health statistics yearbook of 2013, in Chi
-
FDA Approves corcept's mifepristone for Cushing's syndrome
Time of Update: 2012-02-20
Source: China Council for the promotion of drugs (2012-02-20) US regulatory agency gave a green light to corcept's korlym (mifepristone) therapy, which is the first drug approved by FDA for the treatm
-
Xianju Pharmaceutical's Mifepristone Tablets Received Consistency Evaluation Acceptance Notice
Time of Update: 2021-10-20
On October 15, Xianju Pharmaceutical issued an announcement stating that the company had recently received a notice of acceptance of the consistency evaluation of mifepristone tablets issued by the National Medical Products Administration for the termination of intrauterine pregnancy and emergency contraception .
-
Renfu Medicine: Mifepristone tablets passed the consistency evaluation of generic drugs
Time of Update: 2021-05-03
, a subsidiary of the company, received the "Drug Supplementary Application Approval Notice" from the State Food and Drug Administration on mifepristone tablets (notice Book number: 2020B05143), the drug passed the generic drug quality and efficacy consistency evaluation.
-
Renfu Medicine: Mifepristone tablets passed the consistency evaluation of generic drugs
Time of Update: 2021-04-27
, a subsidiary of the company, received the "Drug Supplementary Application Approval Notice" from the State Food and Drug Administration on mifepristone tablets (notice Book number: 2020B05143), the drug passed the generic drug quality and efficacy consistency evaluation.
-
Renfu Medicine: Mifepristone tablets passed the consistency evaluation of generic drugs
Time of Update: 2021-03-29
, a subsidiary of the company, received the "Drug Supplementary Application Approval Notice" from the State Food and Drug Administration on mifepristone tablets (notice Book number: 2020B05143), the drug passed the generic drug quality and efficacy consistency evaluation.